Regulation of Arginine-vasopressin (AVP)
Completed · Not applicable
Conditions studied: Schizophrenia, Depression
In brief
This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.
Key facts
- Study ID
- NCT02626832
- Run by
- Yale University
- People needed
- 25
- Starts
- 2010-02-01
- Expected to finish
- 2014-12-01
- Last updated by the study team
- 2015-12-10
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- The John Pierce Laboratory — New Haven, Connecticut, United States
- VA Connecticut Healthcare System — West Haven, Connecticut, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.